One study on humans - with autistic children - showed that the oral liposomal group (compared to the transdermal group) exhibited some increases in plasma reduced glutathione, but not in whole-blood glutathione levels following supplementation. The authors stated: "We did not see a change in whole-blood glutathione which suggests that increasing intracellular glutathione may require the use of precursors or building blocks for glutathione". Both groups also showed increases in plasma sulfate and cysteine which the authors attributed to actual breakdown of glutathione in the body.( A clinical trial of glutathione supplementation in autism spectrum disorders. Kern JK et al. Med Sci Monit. 2011 Dec;17(12):CR677-82). This human study was not blinded or placebo-controlled which is the golden standard in medical research.
A randomized clinical trial evaluated whether azithromycin improves pulmonary function in patients with cystic fibrosis infected with Pseudomonas aeruginosa. Patients received either azithromycin 250 mg PO or placebo 3 days per week (Mon, Wed, Fri) for 168 days. At the end of the study, those receiving azithromycin showed greater improvements in FEV1 and had a decrease in pulmonary exacerbations. The azithromycin patient group also weighed an average of kg more than placebo patients which suggests an improvement in nutritional status. The results of this study are consistent with 2 other studies suggesting benefits of azithromycin in CF patients.